September 2016

New Product - MS-2 Step

MS‑2 Step (mifepristone, misoprostol (GyMiso)) contains mifepristone, a synthetic steroid with an antiprogestational action as a result of competition with progesterone at the progesterone receptors and misoprostol, a synthetic analogue of prostaglandin E1. MS‑2 Step is indicated in females of childbearing age for the medical termination of a developing intrauterine pregnancy, up to 63 days of gestation (confirmed by ultrasound). MS‑2 Step is contraindicated in the following situations: lack of access to emergency medical care in the 14 days following the start of treatment (i.e. administration of mifepristone); suspected or confirmed ectopic pregnancy; IUD in place; uncertainty about gestational age; chronic adrenal failure; concurrent long term corticosteroid therapy; suspected or known haemorrhagic disorders or treatment with anti‑coagulants. MS‑2 Step is available as a composite pack containing a green carton with one Mifepristone Linepharma 200 mg tablet and a purple carton with 4 GyMiso misoprostol 200 micrograms tablets (two blisters of two tablets each).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629